temozolomide has been researched along with Central Nervous System Disease in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT)." | 6.71 | Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. ( Abbadessa, A; Bernardi, D; Bordonaro, R; Candela, M; Dell'Oro, S; Ferreri, AJ; Franceschi, E; Latte, G; Mason, W; Pace, A; Perry, J; Reni, M; Stelitano, C; Villa, E; Zaja, F, 2004) |
| "Temozolomide was well tolerated; there were no treatment withdrawals or dose reductions caused by toxicity." | 5.43 | Temozolomide for central nervous system involvement in mycosis fungoides. ( Bird, TG; Child, F; Morris, SL; Wain, EM; Whittaker, S, 2016) |
| "Temozolomide is a well-tolerated alkylating agent, that is able to permeate the blood-brain barrier (BBB), and has additive cytotoxicity when given with radiotherapy (RT)." | 2.71 | Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. ( Abbadessa, A; Bernardi, D; Bordonaro, R; Candela, M; Dell'Oro, S; Ferreri, AJ; Franceschi, E; Latte, G; Mason, W; Pace, A; Perry, J; Reni, M; Stelitano, C; Villa, E; Zaja, F, 2004) |
| "Temozolomide was well tolerated; there were no treatment withdrawals or dose reductions caused by toxicity." | 1.43 | Temozolomide for central nervous system involvement in mycosis fungoides. ( Bird, TG; Child, F; Morris, SL; Wain, EM; Whittaker, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bird, TG | 1 |
| Whittaker, S | 1 |
| Wain, EM | 1 |
| Child, F | 1 |
| Morris, SL | 1 |
| Reni, M | 1 |
| Mason, W | 1 |
| Zaja, F | 1 |
| Perry, J | 1 |
| Franceschi, E | 1 |
| Bernardi, D | 1 |
| Dell'Oro, S | 1 |
| Stelitano, C | 1 |
| Candela, M | 1 |
| Abbadessa, A | 1 |
| Pace, A | 1 |
| Bordonaro, R | 1 |
| Latte, G | 1 |
| Villa, E | 1 |
| Ferreri, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for temozolomide and Central Nervous System Disease
| Article | Year |
|---|---|
Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Central Nervous System Diseases; Dacarba | 2004 |
1 other study available for temozolomide and Central Nervous System Disease
| Article | Year |
|---|---|
Temozolomide for central nervous system involvement in mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Dacarbazine; | 2016 |